"Breakthrough Achievement: Indian-Manufactured CAR-T Cell Therapy Successfully Renders Patient Cancer-Free"
In a significant stride, India's CAR-T cell therapy, an indigenous cancer treatment, recently garnered approval from the Central Drugs Standard Control Organization (CDSCO) for commercial use. This revolutionary therapy involves the genetic reprogramming of a patient's immune system to combat cancer. Dr. (Col) VK Gupta, a distinguished gastroenterologist based in Delhi, stands as the inaugural patient declared "cancer-free" through this breakthrough treatment, which he acquired at a fraction of the cost compared to international alternatives. CAR-T cell therapy entails the manipulation of a patient's T cells, a subset of white blood cells vital for immune response, in a laboratory setting. These modified T cells are engineered to express a chimeric antigen receptor (CAR) protein, enabling them to identify and eliminate cancer cells upon reinfusion into the patient's body. NexCAR19, the pioneering CAR-T cell therapy developed by ImmunoACT, a venture incubated a